Zhong Ji Longevity Science Delays Circular on Cell Lab Stake Acquisition

An announcement from Zhong Ji Longevity Science Group Limited ( (HK:0767) ) is now available.

Zhong Ji Longevity Science Group Limited has announced a further delay in sending a shareholder circular regarding its proposed major and connected transaction to acquire 25% of Asian Integrated Cell Laboratory Limited via the issuance of convertible notes. The circular, which will contain key details of the deal, independent advice, and notice of a special general meeting, is now expected to be dispatched on or before 30 March 2026, extending the timeline for shareholders to review and vote on the acquisition and potentially postponing the company’s next strategic step in expanding its cell-lab portfolio.

The delay reflects the additional time needed to finalise information to be included in the circular, suggesting ongoing work on the financial and transactional disclosures required under Hong Kong listing rules. While procedural in nature, the postponement means investors must wait longer for clarity on the terms and implications of the acquisition, which could influence the group’s future growth trajectory in the regional longevity and cell-science market.

The most recent analyst rating on (HK:0767) stock is a Sell with a HK$0.47 price target. To see the full list of analyst forecasts on Zhong Ji Longevity Science Group Limited stock, see the HK:0767 Stock Forecast page.

More about Zhong Ji Longevity Science Group Limited

Zhong Ji Longevity Science Group Limited, incorporated in Bermuda and listed in Hong Kong, operates within the longevity science and related healthcare sector. The company focuses on strategic investments that expand its presence in advanced cell laboratory services and associated biomedical technologies in Asian markets.

Average Trading Volume: 256,038

Technical Sentiment Signal: Sell

Current Market Cap: HK$318.3M

For an in-depth examination of 0767 stock, go to TipRanks’ Overview page.